Sound Vaccine Secures KRW 180,000,000,000 Capital Commitment from GEM as Company Seeks to Get Uplisted on KOSDAQ
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
SEOUL, South Korea -- Businesswire -- Sound Vaccine, Inc., (“Sound Vaccine”), a leading manufacturer of advanced hearing medical systems and patented hearing healthcare products, is pleased to announce that it has signed an agreement (“Agreement”) with GEM Global Yield LLC SCS (“GGY”), the Luxembourg-based private alternative investment group, to provide Sound Vaccine with a share subscription facility of up to KRW 180,000,000,000 for a 36-month term following June 8, 2023. The share subscription facility will allow Sound Vaccine to draw down funds by issuing ordinary shares to GEM. Sound Vaccine will control the timing and the maximum size of such drawdowns and has no minimum drawdown obligation. Sound Vaccine will issue warrants to GEM to purchase up to 2.7% of the issued ordinary shares of the company. Farazad Investments, a leading advisory services group headquartered in Hong Kong with offices in London advised Sound Vaccine on the transaction.
About Sound Vaccine
Sound Vaccine, Inc. specializes in the research, development, and manufacturing of advanced hearing medical systems and hearing healthcare products patented in the US, Japan, Europe, and many other developed regions. Its flagship innovations are clinically proven by Stanford University School of Medicine.
Founded in 2016, Sound Vaccine has emerged as one of the leading names in the hearing industry. A vast multitude of patents has been filed regarding its innovative TSC (Threshold Sound Conditioning) and MDA (Multi-Dimensional Audiometry) technologies.
Sound Vaccine developed the world's first non-invasive hearing improvement technology using acoustic signals for each frequency band. Through this verified invention, they revolutionized the hearing industry with a wide range of products catering for not only hearing loss patients but also people with normal hearing and wish to prevent hearing loss and improve their golden ear.
“We are thrilled to announce our recent commitment of 180 billion KRW from GEM. This investment not only underscores the tremendous potential of Sound Vaccine but also highlights the confidence and trust that GEM has in our ground-breaking technologies and transformative vision. With this strategic partnership that dramatically increases Sound Vaccine’s valuation, we are well-positioned to accelerate our growth and solidify our position as a pioneering force in the auditory healthcare industry. We are excited about the opportunities ahead and remain committed to delivering innovative solutions that will positively impact the lives of millions worldwide.” - Said Eunyee Kwak, CEO of Sound Vaccine.
About GEM
Global Emerging Markets (“GEM”) is a $3.4 billion, alternative investment group with operations in Paris, New York, and The Bahamas. GEM manages a diverse set of investment vehicles focused on emerging markets and has completed over 580 transactions in 75 countries. Each investment vehicle has a different degree of operational control, risk-adjusted return, and liquidity profile.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230613142847/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Sound Vaccine, Inc.
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 송도국제캠핑장, 바베큐장 ‘더 팜 송도’ 그랜드 오픈 - 뉴스와이어
- 김명중 사진작가와 프로쉬 ‘22세기 유물전’ 개최 - 뉴스와이어
- 벼룩시장 조사, 직장인 10명 중 9명 ‘고용불안 느낀다’ - 뉴스와이어
- 반스 월드 2, 로블록스에서 새로운 스케이트 챌린지 선보여 - 뉴스와이어
- 해양수산부, 제10회 해양수산 창업콘테스트 개최 - 뉴스와이어
- 평창 여름 행사 ‘시원한 여름, 신나는 여름, 맛있는 여름’ 개최 - 뉴스와이어
- ‘역대 최대 115만여 명 참가’ 제21회 서울국제환경영화제 성공적 마무리 - 뉴스와이어
- HL만도 주차로봇 ‘파키’ 인천국제공항서 발렛파킹 실증 운영 - 뉴스와이어
- 증가하는 청년 자살… 청년이 직접 자살예방 활동을 하는 ‘청년 자살예방 서포터즈 3기’ 출발
- AI 버추얼 아티스트 수비, 디지털 싱글 ‘SUNCREAM’ 콘셉트 포토 공개 - 뉴스와이어